The HUB comprises 43 institutions, including research hospitals (“IRCCS”), general hospitals, universities, and research centers, 8 of which function as first-level spokes, 16 as level 2A spokes, and 19 as level 2B spokes.

This heterogeneous group of Italian clinicians and scientists, affiliated with both public and private healthcare and academic institutions, with varying levels of expertise and technological infrastructure in different areas of human diseases, will work together for the production of new diagnostic approaches that integrate clinical, phenotypic, and omics data into the clinical decision-making process for well-selected patients. These patients can then benefit from targeted and innovative therapies.

The Metodology

The partners will periodically verify if the project’s approach is in line with available technologies, implementing sustainable strategic and economic choices. In this context, the collaboration of INNOVA with the R&D division of diagnostic companies and startups will be strategic for the validation of development and the commercial enhancement of diagnostic devices.

The network will utilize innovative methodologies and strategies for the collection and analysis of clinical and laboratory data, organized in a step-wise structure:

  • collection of clinical and laboratory data to perform accurate phenotypic characterization;
  • creation of standardized methods for exchanging work protocols;
  • development and facilitation of the availability of local and core service packages for biochemical and molecular laboratory biomarkers associated with the aforementioned non-communicable diseases;
  • implementation of local and core facilities for high-resolution morphological imaging of organs, functional imaging of target tissues, and molecular imaging;
  • integration of multiomic data (radiomics, cell-type-specific high-throughput genomics, epigenomics, transcriptomics, etc.);
  • Integration, through artificial intelligence, of clinical, imaging, phenotypic, and omic data for the identification of specific diagnostic pathways for pathology and potential therapeutic response markers.

Work Package

A technological infrastructure and methods for specific organ microvascular dysfunction
Leader: Maggiore (SD: F. Blandini, PI: F. Peyvandi)
Co-leader: Gemelli (SD: G. Scambia, PI: M. Sanguinetti)

a NHS Service to enhance the informative content of diagnostic imaging
Leader: HSM (SD: A. Uccelli, PI: G. Sambuceti)
Co-leader: Humanitas (SD: A. Mantovani, PI: L. Politi)

A multidisciplinary platform to process innovative immunity and inflammatory biomarkers for precision medicine
Leader: Humanitas (SD: A. Mantovani, PI: C. Garlanda)
Co-leader: HSM (SD: A. Uccelli, PI: G. Filaci)

A high-resolution Liquid Biopsy-based national reference hub for next generation diagnostics leveraging
Leader: IRE/IFO (SD: G. Ciliberto, PI: G. Blandino)
Co-leader: Pascale (SD: A. Budillon, PI: N. Normanno)

Multimodal data harvesting and merging tools for the creation of reliable predictive models
Leader: Gemelli (SD: G. Scambia, PI: M. Sanguinetti)
Co-leader: OSM-PV (SD: V. Bellotti, PI: E. Arbustini)

Multiomics and radiomics pipe
Leader: OSM-PV (SD: V. Bellotti, PI: E. Arbustini)
Co-leader: Neuromed (SD: L. Frati, PI: G. Lembo)

A platform for multiomic profiling and predictive algorithms of resistance to target therapy and immunotherapy
Leader: Pascale (SD: A. Budillon, PI: N. Normanno)
Co-leader: IRE-IFO (SD: G. Ciliberto, PI: G. Blandino)

Platforms and diagnostic products for early diagnosis and prevention of degenerative diseases
Leader: Neuromed (SD: L. Frati, Scientific PI: N. D’Ascenzo)
Co-leader: Maggiore (SD: F. Blandini, Scientific PI: F. Peyvandi)

Leader: Maggiore (SD: F. Blandini, Scientific PI: F. Peyvandi)